Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.

[1]  H. Cohen,et al.  Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Arenillas,et al.  Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group , 2017, American journal of hematology.

[3]  J. Reynolds,et al.  Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients , 2017, American journal of hematology.

[4]  A. Secord,et al.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.

[5]  B. Leber,et al.  Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS‐CAN prospective study , 2016, British journal of haematology.

[6]  R. Stauder,et al.  Clinical judgement and geriatric assessment for predicting prognosis and chemotherapy completion in older patients with a hematological malignancy , 2016, Leukemia & lymphoma.

[7]  E. Giltay,et al.  Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly. , 2016, Acta oncologica.

[8]  G. Abel,et al.  Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. , 2015, Journal of geriatric oncology.

[9]  K. Anderson,et al.  Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. , 2015, Blood.

[10]  E. Giltay,et al.  Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma , 2015, Leukemia & lymphoma.

[11]  H. Wildiers,et al.  Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[13]  M. Federico,et al.  Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi , 2014, Leukemia & lymphoma.

[14]  M. Lübbert,et al.  Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome , 2013, Haematologica.

[15]  J. Williamson,et al.  Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. , 2010, Blood.

[16]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[17]  U. Germing,et al.  Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. , 2011, Leukemia research.

[18]  S. Kritchevsky,et al.  The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia , 2011, Journal of the American Geriatrics Society.

[19]  S. Culine,et al.  Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Khodabakhshi,et al.  Factors leading oncologists to refer elderly cancer patients for geriatric assessment , 2011 .

[21]  G. Mufti,et al.  Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. , 2010, Critical reviews in oncology/hematology.

[22]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Stuck,et al.  Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[25]  N. Howlader,et al.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. , 2008, Blood.

[26]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Studenski,et al.  Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults , 2006, Journal of the American Geriatrics Society.

[28]  S. Inouye.  Delirium in older persons. , 2006, The New England journal of medicine.

[29]  L. Ferrucci,et al.  Phenotype of frailty: characterization in the women's health and aging studies. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  H. Cohen,et al.  Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). , 2005, Critical reviews in oncology/hematology.

[31]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[33]  D. Oscier,et al.  Establishing the incidence of myelodysplastic syndrome , 1994 .